文献速递乳腺癌支持与姑息治疗

多奈哌齐治疗乳腺癌幸存者辅助化疗后认知障碍的III期随机安慰剂对照临床试验(WF-97116)

Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).
PubMed 文献 · J Clin Oncol · 2024-05-06

该III期随机安慰剂对照试验纳入276例辅助化疗后1-5年报告癌症相关认知障碍的乳腺癌幸存者,随机接受多奈哌齐5mg每日一次6周后滴定至10mg每日一次共18周或安慰剂。24周时两组HVLT-R记忆评分无显著差异(多奈哌齐均值25.98 vs 安慰剂26.50,P=0.32),其他认知域及自报认知功能在各时间点亦无统计学显著差异。

要点

  • 多奈哌齐5-10mg每日一次治疗24周未改善乳腺癌幸存者化疗后记忆功能。
  • 24周时HVLT-R评分多奈哌齐组均值25.98 vs 安慰剂组26.50,P=0.32。
  • 注意、执行功能、言语流畅性、处理速度及自报认知功能均无统计学显著差异。

核心结论

  • 辅助化疗后1-5年有记忆问题的乳腺癌幸存者,随机接受24周多奈哌齐5-10mg每日一次,治疗结束时记忆、其他认知功能或主观功能与安慰剂组无差异。

研究设计与样本

  • III期随机、安慰剂对照临床试验,入组276例辅助化疗后1-5年报告癌症相关认知障碍的成年女性乳腺癌幸存者。
  • 受试者来自Wake Forest NCI社区肿瘤研究计划(NCORP)研究基地附属站点,随机分配至多奈哌齐组(n=140)或安慰剂组(n=136)。
  • 多奈哌齐5mg每日一次用6周后滴定至10mg每日一次共18周;安慰剂组方案未在摘要中详述。
  • 在基线、随机后12、24(干预结束)和36(洗脱)周评估认知及自报认知功能。
  • 采用混合效应重复测量协方差分析模型评估HVLT-R即刻回忆(主要结局)及其他认知域(次要结局)。

主要发现

  • 24周时两组HVLT-R评分无显著差异(多奈哌齐均值25.98 vs 安慰剂均值26.50,P=0.32)。
  • 12、24或36周时,注意、执行功能、言语流畅性、处理速度或自报认知功能方面两组均无统计学显著差异。
  • 内分泌治疗和绝经状态不影响结果。
  • 受试者平均年龄57.1岁(标准差10.5),随机化时距化疗平均29.6个月(标准差14.2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To test efficacy of donepezil, a cognitive enhancer, to improve memory in breast cancer survivors who report cancer-related cognitive impairment 1-5 years postchemotherapy. PATIENTS AND METHODS: Adult female BCS exposed to ≥4 cycles of adjuvant chemotherapy 1-5 years before enrollment who reported cancer-related cognitive impairment were eligible. Participants, enrolled at sites affiliated with the Wake Forest NCI Community Oncology Research Program (NCORP) Research Base, were randomly assigned to receive 5 mg of donepezil once daily for 6 weeks titrated to 10 mg once daily for 18 weeks or placebo. Cognition and self-report cognitive functioning was assessed at baseline, 12, 24 (end of intervention), and 36 (washout) weeks postrandomization. Mixed-effects repeated measures analysis of covariance models were used to assess treatment differences in immediate recall (primary outcome) on the Hopkins Verbal Learning Test-Revised (HVLT-R) and other cognitive domains (secondary outcomes) with covariates of treatment, time, time by treatment interaction, baseline outcome level, age stratification, and an unstructured covariance matrix to account for within participant correlation over time. RESULTS: Two hundred seventy-six BCS from 87 NCORP practices (mean age, 57.1, standard deviation [SD], 10.5) who were at a mean of 29.6 months (SD, 14.2) postchemotherapy were randomly assigned to donepezil (n = 140) or placebo (n = 136). At 24 weeks, treatment groups did not differ on HVLT-R scores (donepezil mean = 25.98, placebo = 26.50, P = .32). There were no statistically significant differences between treatments at 12, 24, or 36 weeks for attention, executive function, verbal fluency, processing speed, or self-reported cognitive functioning. Endocrine therapy and menopausal status did not affect results. CONCLUSION: BCS 1-5 years after completing chemotherapy with documented memory problems, randomly assigned to 24 weeks of 5-10 mg of donepezil once daily, did not perform differently at the end of treatment on tests of memory, other cognitive functions, or subjective functioning than those randomly assigned to placebo.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rapp SR, Dressler EV, Brown WM, et al. Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116). J Clin Oncol. 2024. PMID: 38709986. doi:10.1200/JCO.23.01100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。